Skip to content

Multicenter, randomly simpling, nutrition combination scheme Dai Li le efficacy and safety of clinical studies in patients with advanced lung cancer

Multicenter, randomly simpling, nutrition combination scheme Dai Li le efficacy and safety of clinical studies in patients with advanced lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-14005023
Enrollment
Unknown
Registered
2014-07-23
Start date
2014-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:Nutrition combination plan

Sponsors

Changhai Hospital Affiliated to Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) patients diagnosed with lung cancer; (2) age 18 to 65 years old, gender not limited; (3) to understand the purpose of testing, voluntary participation and sign a consent form.

Exclusion criteria

Exclusion criteria: (1) to the study of pharmaceutical ingredients known allergies; (2) the tumor of lung cancer patients, patients with HIV positive; (3) the experiment is contraindicated in patients with severe chronic diseases; (4) the liver function damage, SGPT and SGOT 3 times greater than the upper limit of normal value; (5) the abnormal renal function, serum creatinine (Cr) 1.5 times greater than the upper limit of normal; (6) with severe systemic disease, such as cardiovascular, respiratory, digestive, nervous, endocrine, urogenital system diseases, etc.) and the condition is not stable; (7) have a pregnancy (at the first visit by urine pregnancy test to determine), ready for pregnancy during the tests are lactating women; (8) has a history of drug abuse or alcohol; (9) within 30 days before the test for other drug clinical trial; (10) the researchers determine patient adherence is poor, could not finish my study in accordance with the requirements; (11) have a brain, bone metastases, a large number of patients with pleural effusion. Pain, is not competent for treatment of patients; (12) treatment 2 weeks still obvious gastrointestinal reaction, reaction of chemotherapy patients with very obvious.

Design outcomes

Primary

MeasureTime frame
IgA;IgM;IgE;NIF;interleukin;CD6;CD8;CD6/CD8;

Secondary

MeasureTime frame
Tumor markers;

Countries

China

Contacts

Public Contactcai dong lian
nutrition1226@sina.com+86 13636329318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026